|Dr Sarah Bell|
|Dr Pete Chong|
|Professor Carien L. Creutzberg, MD, PhD
Professor, Department of Radiation Oncology
Leiden University Medical Center
Leiden, the Netherlands
Carien Creutzberg is Professor of Radiation Oncology at the Department of Radiation Oncology at Leiden University Medical Center, the Netherlands. Both her clinical and scientific work has been focused on Radiation Therapy for Gynecological Cancers. She is chief investigator of the four PORTEC-trials on adjuvant treatment of women with endometrial cancer.
|Mrs Willemien van Driel
Willemien works as a gynaecologic oncologist in the Center for Gynaecologic Oncology Amsterdam (CGOA) since 2004. She currently chairs the Dutch Oncology Working Group and is PI of the phase III randomized trial investigating the effect of HIPEC in the treatment of advanced stage ovarian cancer.
|Professor Richard Edmondson, St Mary's Hospital, Manchester, UK
Richard Edmondson qualified in medicine from Newcastle University in 1992 and after a year of surgical training in New Zealand undertook speciality training in the Northern Deanery in Obstetrics and Gynaecology with subspecialty training in Gynaecological Oncology at the Queen Elizabeth Hospital, Gateshead. He was awarded an MD from Newcastle University in 2002 for his work investigating the biology of the ovarian surface epithelium which led to his current interest in ovarian cancer biology.
He was appointed as a consultant in Gateshead and honorary senior lecturer in Newcastle in 2005 and since then, in addition to developing techniques in extended surgery for ovarian cancer, he has developed a translational research group investigating potential therapeutic biomarkers. His group has developed techniques to establish real time models for ex vivo testing of drug sensitivity alongside functional assessment of the tumour and this has led to exciting developments in the ability to predict response to novel agents including PARP inhibitors as well as conventional chemotherapy agents such as carboplatin.
In addition he chairs the endometrial subgroup of the NCR clinical studies group and works to increase the number and breadth of portfolio studies in endometrial cancer.
In January 2014 he took up the chair of Gynaecological Oncology at the University of Manchester.
|Dr Christina Fotopoulou, Imperial College Healthcare Trust, London, UK
Professor Christina Fotopoulou trained in in obstetrics and gynaecology and subspecialized in gynaecological oncology at the Charité University Hospital of Berlin in the surgical and systemic treatment of women with advanced gynaecological malignancies. She is since 2013 a Consultant Cynecological Oncologist in the Imperial College London Healthcare Trust in Queen Charlottes Hospital in London, and is a principal investigator of the Ovarian Cancer Action Research Centre, UK. She also holds a chair at the Charite University of Berlin. She has been the Vice Director of the Clinic for Gynecology at the Charité in Berlin, one of the largest reference and accredited centers for gynecological cancer in Europe, as well the Principal Coordinator of the European Competence Center for Ovarian Cancer.
Her principal area of expertise lies in exenterative procedures for advanced forms of pelvic malignancies, in the cytoreductive procedures for primary or relapsed ovarian cancer and the investigation of predictive and prognostic biomarkers of surgical and clinical outcome. Her further area of focus is bioengineering and implementation of novel bioengineering methods in cytoreductive surgery for advanced ovarian cancer.
She the lead of the guidelines group of the British Gynaecological Cancer Society, member of the QA Committee for Ovarian Cancer surgery of ESGO and member of the German AGO- Ovarian Cancer Steering Group and Guidelines. She is on the editorial board and reviewer of numerous international gynaecological and oncological journals and is member of various international oncological committees, including BGCS, ASCO, ESGO, IGCS, ESMO, ENGOT, AGO, SGO and NOGGO.
|Dr Sadaf Ghaem-Maghami
Sadaf Ghaem-Maghami is an associate professor and a consultant in gynaecological oncology at Imperial College London. Her research interests are in immunology and immunotherapy of ovarian cancer and biomarker discovery for personalisation of ovarian cancer surgery. She chairs the Scientific Advisory Committee of the RCOG and is a member of FIGO research subcommittee.
|Dr Ros Glasspool
Ros is a consultant medical oncologist and senior NRS research fellow at the Beatson West of Scotland Cancer Centre, specialising in the treatment of ovarian cancer. Her current research focuses on the development of novel therapies for women with ovarian cancer and identifying ways of targeting these therapies to those most likely to benefit. She is the chair of the NCRI CSG ovarian cancer sub-group, ovarian cancer trial coordinator for the Scottish Gynaecological Cancer Trials Group and co-chair of the ENGOT phase I/II trials group
|Dr Marcia Hall
Trained in medicine at Guy’s Hospital Medical School - q1986. Completed PhD at the Imperial Cancer Research Fund (now CRUK) working on cyclins / kinases / and their inhibitors p15/16ARF and p21 (very novel at the time!).
Based at Mount Vernon Cancer Centre, but visiting Hillingdon Hospital and Wexham Park Hospitals, Dr Hall is predominantly a ‘clinical triallist’ with a large patient base. Her main interest is in gynaecological cancers but she also sees and treats colorectal and anal cancers. She is PI of many clinical trials at MVCC and Chief Investigator of the METRO-BIBF, OSCAR, RaNGO and CeNTurIOn studies in gynaecological cancers and CoRINtH and AMPhiTHEatRe phase 1b studies in anal cancer. A member of the National Cancer Research Institiute (NCRI) Ovarian Cancer subgroup –and active participant on the Guideline Development Group for Ovarian Cancer convened under the umbrella of NICE. Her professional aims are to care effectively for patients with gynaecological, colorectal and anal cancers, using evidence-based medicine where available and offering research trials of drugs and/or techniques under development or in areas of controversy. She is currently Lead Clinician for Research and Development at Mount Vernon Cancer Centre.
Outside of medicine (– if there is any outside!), she has a great interest in music, an ambition to take grade 8 piano exam at some stage… a very interested and committed gardener with a burgeoning vegetable plot and cutting flower patch. She enjoys the satisfaction of bringing in the harvest and preparing meals with this when she has the time and three almost-grown up children have grown used to fishing out the caterpillars. Sadly none interested in medicine, which she suspects keeps her sane!
|Dr Emma Hudson, South Wales Cancer Centre, Cardiff, UK
|Mr Thomas Ind
Consultant Gynaecological Oncology Surgeon and Head of Department, Royal Marsden & St George’s Hospitals London
Thomas Ind trained in London, & Sydney. He has a particular interest in laparoscopic & robotic surgery; fertility sparing surgery for cervical cancer; and the holistic management of women with endometrial cancer & multiple co-morbidities. Thomas ind has multiple publications, book chapters and academic grants. His most prominent current academic work involves novel methods for imaging in cervical cancer prior to trachelectomy. This team has received many prestigious grants including those from MRC, CRUK, & Wellcome foundation. This team reached the finals of the BMA team of the year award. He was an early embracer of laparoscopic surgery having had specific training for this in Sydney in the mid 90s. More recently has has developed robotic surgery at the Royal Marsden Hospital and was one of two surgeons who performed the first gynaecological robotic case in the UK nearly ten years ago in November 2007. Since then he has progressed through different robotic platforms and studied the role of ICG in lymphadenectomy and sentinel node dissection. He has spent five years as treasurer of the BSGE and is currently the treasurer of BGCS. He is very active in societal work and is also President of BIARGS and Secretary/Treasurer of SERGS.
|Professor Gemma Kenter
Gemma Kenter (1952) studied medicine in Amsterdam and did her specialty training in Leiden. Since 2005 she is full professor in Gynaecologic Oncology. She is head of the Center for Gynaecologic Oncology in Amsterdam, a cooperation between the University Medical Centers and the Dutch Cancer Center. Her main scientific interest concerns cervical cancer.
|Professor W Glenn McCluggage
I am a consultant Histopathologist in Royal Group of Hospitals Trust, Belfast and an Honorary Professor in Gynaecological Pathology of Queen’s University of Belfast. I have published well over 400 papers in peer reviewed journals, including original publications and many invited editorials and reviews. I am on the Editorial Board of several major pathology journals and associate editor of Histopathology. I am immediate past President of International Society of Gynecological Pathologists and was previously secretary of this society. Previously I was President of the British Association of Gynaecological Pathologists. I have an extremely busy referral practice and have been invited to lecture at numerous national and international meetings. I have authored or coauthored the various Royal College of Pathologists datasets in United Kingdom on reporting of gynaecological malignancies and have chaired the ICCR (International Collaboration on Cancer Reporting) panels developing international guidelines for reporting endometrial, ovarian and cervical carcinomas. I have been part of the last 2 WHO groups formulating the classification of Tumours of the Female Genital Tract.
|Professor Iain McNeish, University of Glasgow, UK
Iain McNeish is Professor of Gynaecological Oncology at the Institute of Cancer Sciences, University of Glasgow, and honorary consultant in Medical Oncology at the Beatson West of Scotland Cancer Centre. He is also the current chair of the NCRI Gynaecological CSG. His lab research focuses on developing novel therapies for ovarian cancer based upon a greater understanding of disease biology from genomics and improved preclinical models.
|Professor Philippe Morice
Philippe Morice is the head of the Departments of Surgery in Gustave Roussy, Villejuif France and Full Professor at the University Paris-Sud. His main topics of clinical and translational research are: conservative management of gynecologic cancer, borderline ovarian tumors, cancer and pregnancy, radical surgery in advanced stage ovarian cancer, results and interest of lymphadenectomy in gynecological malignancies, interest of completion surgery after chemoradiation therapy in stage IB2/II cervical cancer, impact of radiation therapy and btachytherapy on uterine myocontractility and fertility
|Professor Scott Nelson
Scott Nelson is the Muirhead Chair in Obstetrics and Gynaecology at the University of Glasgow. He undertook his medical training in Glasgow with a PhD in fetal therapy from the University of Dundee. Further clinical academic training was undertaken in Glasgow as a Clinician Scientist in maternal medicine and assisted conception. Professor Nelson’s particular area of expertise is in the use of biomarkers to individualize care. He has published more than 120 manuscripts including landmark papers on assisted conception in The Lancet, JAMA and Plos Medicine. He currently holds grants from the US National Institute of Health, The European Union, Wellcome Trust and the UK Medical Research Council in reproductive medicine.
|Professor Nick Reed|
|Professor Andrea Rockall|
|Dr Evis Sala
Dr. Sala is an academic radiologist with a special interest in Cancer Imaging. She is an established researcher with 162 peer-reviewed publications, 197 invited lectures and multiple research grants. Her research focuses on development of functional imaging biomarkers of evaluation of treatment response, as well as quantification of tumor heterogeneity and its correlation with pathology and genomic analysis.
|Dr Alex Taylor|
|Mr John Telfer
Mr John Telfer is Consultant Plastic Surgeon at the Canniesburn Plastic Surgery Unit, Glasgow Royal infirmary. He graduated from Edinburgh University in 1985. He trained in Edinburgh, Glasgow and London before taking up a substantive post in Glasgow. He has considerable experience in many areas of cosmetic and reconstructive surgery, but particularly in Gynaecological and Perineal Reconstruction. He has worked closely with the Gynaecologists and Colorectal Surgeons in Glasgow for the last 16 years managing patients with Cancer and a wide variety of other conditions.
|Professor Ate G.J. van der Zee, M.D., Ph.D.
Professor of Gynaecological Oncology, University Medical Center Groningen
Vice President Board of Directors University Medical Center Groningen
Birth year: 1960
Professor van der Zee is a Professor of Gynecologic Oncology, University Medical Center Groningen. The Department of Gynecologic Oncology, University Medical Center Groningen, is one of the world leading centers with respect to clinical and translational research in Gynecologic Oncology. Professor Van der Zee has recently initiated and established a managed clinical network for ovarian cancer for all hospitals in the North-East of the Netherlands (catchment area 3.5 million people), in which gynecologists and medical oncologists collaborate to improve the care for ovarian cancer patients and which forms a unique platform for translational research. Prof. Van der Zee has also created a long and productive translational research line on prognostic and predictive factors in gynecologic cancer. He is leading a world-wide consortium (GROINSS-V-II), which performs landmark clinical studies in vulvar cancer. He co-authored > 200 peer-reviewed publications. Under his guidance 39 PhD theses were completed. Since January 2013, he joined the Board of Directors of the University Medical Center Groningen. He combines his management position with clinical research, performing surgery in Gynaecological Oncology, seeing patients during consulting hours, academic research and mentoring PhD students.
Professor Van der Zee is past President of the European Society for Gynecologic Oncology (2009 – 2011) and past president of the Dutch Working Party for Gynecologic Oncology. He serves and has served on various national and international advisory and program committees (eg. Dutch Cancer Society, NCRN UK, IGCS, ESGO, etc.). He is senior editor of the International Journal of Gynaecological Cancer.